// App-Quantinova.ai

OC 50.2 : Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin: Analysis of Antithrombin Levels and Thrombin Generation from a Phase 3 Study in People with Hemophilia A or B Without inhibitors

Researchers

Presenter

  • S. Pipe

Principal Investigators

  • A. Srivastava

  • R. Klamroth

  • G. Kenet

  • H. Tran

  • Z. Qiu

  • S. Andersson

  • B. Mei

  • S. Rangarajan

Medical Centers

  • University of Michigan Medical School, Ann Arbor, Michigan, United States

  • Christian Medical College, Vellore, India, Vellore, Tamil Nadu, India

  • Vivantes Klinikum Am Friedrichshain, Berlin, Germany

  • The National Haemophilia Centre, The Amalia Biron Thrombosis Research Institute, Sheba Medical Centre, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel, Tel Aviv, Tel Aviv, Israel

  • Department of Clinical Hematology, The Alfred Hospital, Melbourne, Australia AND Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia, Melbourne, Victoria, Australia

  • Sanofi Genzyme, Paris, France, Paris, Ile-de-France, France

  • Sanofi, Bridgewater, NJ, USA, Bridgewater, New Jersey, United States

  • Sanofi, Cambridge, MA, USA, Cambridge, Massachusetts, United States

  • University of Southampton, Southampten, United Kingdom

Locations

  • United States

  • India

  • Germany

  • Israel

  • Australia

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • Evithrom

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multinational

Phase

  • III

Study Id's

  • NCT03417245

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved